| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 11-03-2022 | 09-30-2022 | 10-Q | |
| 2 | 08-08-2022 | 06-30-2022 | 10-Q | |
| 3 | 05-10-2022 | 03-31-2022 | 10-Q | |
| 4 | 03-22-2022 | 12-31-2021 | 10-K |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
CinCor Pharma, Inc. ("CinCor" or the "Company") announced today completion of an End-of-Phase 2 meeting with t...
Barclays analyst Leon Wang downgrades CinCor Pharma (NASDAQ:CINC) from Overweight to Equal-Weight and raises the price targe...
Morgan Stanley analyst Jeffrey Hung maintains CinCor Pharma (NASDAQ:CINC) with a Equal-Weight and raises the price target fr...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday.
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the comp...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Monday.
U.S. stocks traded higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses...
